98 related articles for article (PubMed ID: 9058162)
61. Mast cell density and the context of clinicopathological parameters and expression of p185, estrogen receptor, and proliferating cell nuclear antigen in gastric carcinoma.
Jiang YA; Zhang YY; Luo HS; Xing SF
World J Gastroenterol; 2002 Dec; 8(6):1005-8. PubMed ID: 12439914
[TBL] [Abstract][Full Text] [Related]
62. Membranous levels of c-erbB-2 oncoprotein in gastric cancer: their relationship with clinicopathological parameters and their prognostic significance.
Vizoso FJ; Corte MD; Alvarez A; García I; del Casar JM; Bongera M; González LO; García-Muñiz JL; Allende MT
Int J Biol Markers; 2004; 19(4):268-74. PubMed ID: 15646832
[TBL] [Abstract][Full Text] [Related]
63. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas.
Carneiro F; Sobrinho-Simoes M
Cancer; 2000 Jan; 88(1):238-40. PubMed ID: 10618628
[No Abstract] [Full Text] [Related]
64. Expression of the c-erbB-2 proto-oncogene product in gastric carcinoma and precancerous lesions.
Mi JQ; Yang SQ; Shen MC
World J Gastroenterol; 1997 Jun; 3(2):122. PubMed ID: 27041970
[TBL] [Abstract][Full Text] [Related]
65. Prognostic significance of c-erbB2 overexpression in patients with metastatic gastric cancer.
Bayrak M; Olmez OF; Kurt E; Cubukcu E; Evrensel T; Kanat O; Manavoglu O
Clin Transl Oncol; 2013 Apr; 15(4):307-12. PubMed ID: 22911549
[TBL] [Abstract][Full Text] [Related]
66. C-erbB-2 expression and prognosis of gastric cancer: a meta-analysis.
Wang ZQ; Sun BJ
Genet Mol Res; 2015 Mar; 14(1):1782-7. PubMed ID: 25867322
[TBL] [Abstract][Full Text] [Related]
67. Expression and prognostic value of c-erbB-2 oncogene product in human phaeochromocytomas.
Castilla-Guerra L; Moreno AM; Fernández-Moreno MC; Utrilla JC; Fernández E; Galera-Davison H
Histopathology; 1997 Aug; 31(2):144-9. PubMed ID: 9279565
[TBL] [Abstract][Full Text] [Related]
68. [Expression of soluble c-erbB-2 protein in serum of gastric cancer patients: preliminary report].
Nakai M; Yonemura Y; Tsugawa K; Fushida Y; Yamaguchi A; Miwa K; Miyazaki I
Nihon Geka Gakkai Zasshi; 1992 Mar; 93(3):337. PubMed ID: 1355258
[No Abstract] [Full Text] [Related]
69. [Expression and clinical significance of epidermal growth factor receptor，HER2, PI3Kp110α and PI3Kp110β in gastric carcinoma].
Li SM; Wu SH
Zhonghua Bing Li Xue Za Zhi; 2016 Jun; 45(6):407-8. PubMed ID: 27256050
[No Abstract] [Full Text] [Related]
70. C-erbB-2 expression is related with pathological progression of gastric cancer: results of a non-radioactive in situ hybridization.
Wang K; Liu J; Duan Y; Wu J; Dongye S; Wang Y; Liu Z; Han G
Int J Clin Exp Pathol; 2017; 10(9):9649-9653. PubMed ID: 31966845
[TBL] [Abstract][Full Text] [Related]
71. [Stomach cancer. Morphology].
Nasierowska-Guttmejer A; Majewski P; Malinowska M
Pol J Pathol; 2013 Dec; 64(4 Suppl 2):s27-39. PubMed ID: 24893506
[No Abstract] [Full Text] [Related]
72. "HER majesty's a pretty nice girl but she changes from day to day".
Bohanes P; Loupakis F; Labonte MJ; Wakatsuki T; Lenz HJ
J Clin Oncol; 2012 Feb; 30(4):465-6; author reply 466-7. PubMed ID: 22203763
[No Abstract] [Full Text] [Related]
73. Intratumoral heterogeneity in gastric cancer: a new challenge to face.
Alsina M; Gullo I; Carneiro F
Ann Oncol; 2017 May; 28(5):912-913. PubMed ID: 28368465
[No Abstract] [Full Text] [Related]
74. Evaluation of Lapatinib Powder-Entrapped Biodegradable Polymeric Microstructures Fabricated by X-Ray Lithography for a Targeted and Sustained Drug Delivery System.
Jeong EG; Yoo HJ; Song B; Kim HP; Han SW; Kim TY; Cho DD
Materials (Basel); 2015 Feb; 8(2):519-534. PubMed ID: 28787954
[TBL] [Abstract][Full Text] [Related]
75. Immunohistochemical Analysis of p53, Ki-67, CD44, HER-2/neu Expression Patterns in Gastric Cancer, and Their Association with One Year Survival in North-West of Iran.
Sanaat Z; Halimi M; Ghojezadeh M; Pirovi AH; Gharamaleki JV; Ziae AE; Kermani IA
Int J Hematol Oncol Stem Cell Res; 2013; 7(3):15-20. PubMed ID: 24505530
[TBL] [Abstract][Full Text] [Related]
76. Prognostic significance of HER2/neu expression in gastric cancer.
Ananiev J; Gulubova M; Manolova I; Tchernev G
Wien Klin Wochenschr; 2011 Jul; 123(13-14):450-4. PubMed ID: 21739203
[TBL] [Abstract][Full Text] [Related]
77. Pharmacogenomics in chemotherapy for GI tract cancer.
Furuta T
J Gastroenterol; 2009; 44(10):1016-25. PubMed ID: 19728007
[TBL] [Abstract][Full Text] [Related]
78. HER-2/neu amplification is an independent prognostic factor in gastric cancer.
Park DI; Yun JW; Park JH; Oh SJ; Kim HJ; Cho YK; Sohn CI; Jeon WK; Kim BI; Yoo CH; Son BH; Cho EY; Chae SW; Kim EJ; Sohn JH; Ryu SH; Sepulveda AR
Dig Dis Sci; 2006 Aug; 51(8):1371-9. PubMed ID: 16868827
[TBL] [Abstract][Full Text] [Related]
79. Transcriptome analysis of human gastric cancer.
Oh JH; Yang JO; Hahn Y; Kim MR; Byun SS; Jeon YJ; Kim JM; Song KS; Noh SM; Kim S; Yoo HS; Kim YS; Kim NS
Mamm Genome; 2005 Dec; 16(12):942-54. PubMed ID: 16341674
[TBL] [Abstract][Full Text] [Related]
80. The expression of c-erbB-1 and c-erbB-2 in Iranian patients with gastric carcinoma.
Ghaderi A; Vasei M; Maleck-Hosseini SA; Gharesi-Fard B; Khodami M; Doroudchi M; Modjtahedi H
Pathol Oncol Res; 2002; 8(4):252-6. PubMed ID: 12579211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
